
Advertise on podcast: tHEORetically Speaking
This podcast has
74 episodes
Language
EnglishPublisher
HealthEconomics.comExplicit
No
Date created
2025/07/10
Latest episode
2026/02/06
Average duration
7 min.
Release period
9 days
Description
Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/
Unlock tHEORetically Speaking podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from tHEORetically Speaking podcast
Weekly News Roundup — Regulatory RWE Battles, Capital Market Moves, and Cash-Pay Drug Pricing Disruption
2026/02/06
This week's tHEORetically Speaking News Roundup covers Humana’s rollout of a Google Cloud–powered AI tool to streamline 80 million annual member calls, Amgen’s pushback against the FDA to keep Tavneos on the market using real-world evidence, and AstraZeneca’s NYSE debut to fuel its global growth strategy. We also explore the new TrumpRx portal aimed at expanding discounted cash-pay prescriptions.
Tune in for this concise recap of these pivotal industry updates!
Register for World EPA Congress 2026 here:
https://www.terrapinn.com/EPA/2026/HealthEconomics
INsights & OUTcomes with Taylor Hirschberg
2026/02/02
This episode features Taylor Hirschberg, an award winning writer, activist, and academic. He is the CEO of Metli Consulting, an inclusive consultancy firm focused on helping to prepare for launch and providing a faster, more flexible approach to market access.
Learn more about Metli Consulting: https://www.metliconsulting.com/
“Science without story fails to reach policymakers. Policy without equity fails communities. Story without evidence fails everyone. Metli is a life sciences and public health consulting firm founded at the intersection of science, policy, communications, and human impact.”
Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's next. Join thousands of professionals who trust Health Economics.com as their go to resource. Subscribe for weekly insights, expert commentary, and the latest developments across HEOR and market access: https://healtheconomics.com/subscribe/
Weekly News Roundup — Rare Disease Funding Risks, Medicare Advantage Reform, and Global Trade Shifts
2026/01/30
This week’s tHEORetically Speaking News Roundup covers the looming funding crisis for rare disease biotechs as FDA priority review vouchers expire, CMS’s proposed crackdown on Medicare Advantage upcoding, and Cellares’ $257 million raise to scale automated cell therapy manufacturing. We also explore Sanofi’s defense of vaccines amid shifting U.S. policy and a landmark EU–India free trade agreement set to reshape global pharma access.
Tune in for a concise recap of these pivotal industry updates!
Weekly News Roundup — Oral GLP-1 Momentum, Trade Tensions, EU Drug Security, and AI Risk Warnings
2026/01/23
This week’s tHEORetically Speaking News Roundup covers Novo Nordisk’s early momentum with oral Wegovy amid intensifying GLP-1 competition, rising geopolitical trade tensions threatening pharma market access, and Europe’s push to secure medicine supply chains through the Critical Medicines Act. We also examine new warnings on the misuse of medical AI heading into 2026.
Tune in for this concise recap of the week’s most impactful HEOR, RWE, and market access developments.
Weekly News Roundup — Neurodegeneration Deals, Generative AI, and Drug Pricing Politics
2026/01/16
This week’s tHEORetically Speaking News Roundup covers Novartis’ $1.5B Alzheimer’s licensing deal, the FDA’s push to accelerate drug development through Bayesian trial methods, and Bayer’s move to scale generative AI in antibody discovery. We also break down Oxford Biomedica’s takeover talks and a newly unveiled US healthcare cost plan.
Tune in for a concise recap of these pivotal industry updates!
Weekly News Roundup — Oncology Shakeups, FDA Wellness Crackdown, and AI-Powered Drug Discovery
2025/12/12
This week’s tHEORetically Speaking News Roundup covers GSK’s abrupt exit from its five-year synthetic lethality partnership with Ideaya, Whoop’s escalating regulatory clash with the FDA over its unapproved blood-pressure feature, and new evidence showing how minimum wage and EITC policies improve maternal mental health. We also break down Medra’s $52M raise and its new AI-driven drug-discovery partnership with Genentech.
Tune in for this concise recap of these pivotal industry updates!
Weekly News Roundup — Tariff-Free Pharma, Biologics Modernization, Duchenne Trial Success, and Maternal Health Advances
2025/12/05
This week’s tHEORetically Speaking News Roundup breaks down four major developments shaping policy and biopharma. We cover the new US–UK trade deal exempting pharma from tariffs and resetting NHS pricing, the FDA’s push to curb non-human primate testing for monoclonal antibodies, and Capricor’s breakthrough Phase 3 results in Duchenne muscular dystrophy. We also highlight new HEOR research using copula modeling to better understand drivers of low birth weight and preterm birth.
Tune in for a fast, 4-minute briefing on the most important shifts across science, regulation, and market access.
Weekly News Roundup — Premium Hikes, Predictive AI Breakthroughs, and Public Health Policy Fallout
2025/11/21
This week’s tHEORetically Speaking News Roundup covers Medicare’s 10% Part B premium hike for 2026 and its potential to push more seniors toward Medicare Advantage, Clairity’s $43M raise to expand its FDA-cleared predictive AI platform beyond mammography, and the RISE Committee’s controversial move to exclude public health degrees from its professional program definition.
Tune in for this concise recap of these pivotal policy, innovation, and workforce updates!
Weekly News Roundup — Four Big Moves in Medtech, Neurotech, Biopharma R&D & Pharma M&A
2025/11/14
This week on tHEORetically Speaking, we’re covering four major stories shaping the landscape across medtech, neurotech, drug development, and global pharma: Laborie buys Organon’s Jada system, NextSense raises a new round to launch EEG Smartbuds, Evotec and BMS hit an IND milestone, and Merck goes big with a $9.2B antiviral acquisition.
A fast, focused roundup of the headlines you need to know. Subscribe for weekly drops!
Weekly News Roundup – FDA Shakeups, Novo Nordisk’s Strategic Reset, and Smart Data for Diabetes Innovation
2025/11/07
This week’s tHEORetically Speaking News Roundup covers the sudden resignation of the FDA’s top drug chief amid controversy, Novo Nordisk’s sweeping restructuring and strategic reset in the obesity and diabetes markets, and a groundbreaking data partnership between ŌURA and Tidepool driving innovation in diabetes research. We also explore how rising healthcare costs threaten the future of clinical trial diversity.
Tune in for this concise recap of these pivotal industry updates!
Weekly News Roundup – Neuro Breakthroughs, Biosimilar Reform, and an Obesity Drug Showdown
2025/10/31
This week’s tHEORetically Speaking News Roundup covers Evotec and Bristol Myers Squibb’s progress in developing next-generation therapies for neurodegenerative diseases, the FDA’s game-changing move to streamline biosimilar approvals and lower drug costs, and Novo Nordisk’s bold $6.5B counteroffer to outbid Pfizer for Metsera in the obesity treatment race.
Tune in for this concise recap of the top stories shaping HEOR, RWE, and Market Access this week.
Weekly News Roundup – Real-World Wins and Billion-Dollar Breakthroughs
2025/10/24
This week’s tHEORetically Speaking News Roundup covers Astellas Pharma’s Phase 4 findings showing fezolinetant’s real-world benefits for menopausal symptom relief, improved sleep, and daily functioning. We also dive into Takeda’s $11 billion collaboration with Innovent Biologics to advance next-generation cancer therapies and expand its global oncology pipeline.
Tune in for this concise recap of these pivotal industry updates!
INsights & OUTcomes with Dalfoni Banerjee
2025/10/21
This episode features Dalfoni Banerjee, an award-winning entrepreneur and consultant with over 30 years of hands-on experience and her expertise spans the full drug development cycle.
In 2011, Dalfoni founded and continues to operate 3Sixty Pharma Solutions, which has a mission to support startup and established pharmaceutical, biotechnology, and medical device companies with subject matter experts who help teams accelerate development, overcome challenges, and avoid preventable delays.
Learn more about 3Sixty Pharma Solutions here: https://3sixtypharma.com/
Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's next. Join thousands of professionals who trust Health Economics.com as their go to resource. Subscribe for weekly insights, expert commentary, and the latest developments across HEOR and market access: https://healtheconomics.com/subscribe/
Weekly News Roundup – CAR-T Safety Alerts, Policy Ripple Effects, and Notable Wearables
2025/10/17
This week’s tHEORetically Speaking News Roundup covers the FDA’s new boxed warning for J&J’s CAR-T therapy Carvykti, a major study linking post-Dobbs abortion restrictions to rising intimate partner violence, and Pelage Pharmaceuticals’ $120M funding to advance a next-generation hair loss treatment. We also spotlight Ōura’s $900M investment to expand its AI-driven health tech platform.
Tune in for this concise recap of these pivotal industry updates!
Weekly News Roundup – Immunology, Innovation, and Impact
2025/10/10
This week’s tHEORetically Speaking News Roundup covers nirsevimab’s real-world success in reducing RSV hospitalizations among infants, Boehringer Ingelheim’s FDA approval of Jascayd for idiopathic pulmonary fibrosis, and Arthrosi Therapeutics’ $153 million raise to advance a next-generation gout drug. We also highlight this year’s Nobel Prize in Medicine, honoring discoveries in immune tolerance that continue to shape today’s biggest breakthroughs.
Tune in for this concise recap of these pivotal industry updates!
Podcast reviews
Read tHEORetically Speaking podcast reviews
Podcast sponsorship advertising
Start advertising on tHEORetically Speaking relevant audience podcasts
You may also like to advertise on these Podcasts

4.4371061566
The Megyn Kelly Show
SiriusXM

4.888901269
Fearless with Jason Whitlock
Blaze Podcast Network

4.8118931000
Mind Pump: Raw Fitness Truth
Sal Di Stefano, Adam Schafer, Justin Andrews, Doug Egge

4.8102131585
Tara Brach
Tara Brach

4.541561215
Something You Should Know
Mike Carruthers | OmniCast Media

4.513841343
Strictly Anonymous Confessions
Kathy Kay

4.8292781897
Fantasy Footballers - Fantasy Football Podcast
Fantasy Football

4.62382612
Football Weekly
The Guardian

4.45387666
Two Judgey Girls
Two Judgey Girls

3.8258501152
The Viall Files
Nick Viall